Taiwan Lawmakers Say Government Favors Pharmas In Flu Crisis
This article was originally published in PharmAsia News
Executive Summary
Taiwan legislators accused the nation's health authorities of giving in to pharmaceutical companies and allowing sharp increases in flu antivirals. They said the sharp increases occurred after it was announced the National Health Insurance would cover the cost of prescriptions for Roche's Tamiflu (oseltamivir). Legislators said that following the announcement, the price of the drug increased by 18 percent. One lawmaker said the spike in the price amounts to nearly $23 million for the government. An NHI official said the threat of a pandemic has raised the market price of the drug significantly. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.